AstraZeneca’s new CEO removes R&D, commercial heads

LONDON (Reuters) – AstraZeneca’s new chief executive stamped his authority on the struggling drugmaker on Tuesday by removing the heads of research and commercial operations in a management revamp designed to speed decision-making. Pascal Soriot, who took the helm at Britain’s second-biggest pharmaceutical company in October, said the roles held by Martin Mackay and Tony Zook respectively had been eliminated and both men would leave the company at the end of January. …